Coala-Life Group (COALA.ST) Stock Analysis & AI Equity Report
Coala-Life Group (COALA.ST) overview
Coala-Life Group (COALA.ST) stock analysis and AI equity research. For the latest completed financial year, 2022, Coala-Life Group reported revenue of SEK 16.8m and operating profit of SEK -141m; the year-end share price was 1.74 SEK and market capitalisation was SEK 177m. Coala-Life Group is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Coala-Life Group's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About Coala-Life Group
Coala-Life Group AB is a medical technology and digital health company focused on remote patient monitoring and cardiac diagnostics. It develops and markets the Coala Heart Monitor and related software for ECG and heart sound recording, serving healthcare providers with long-term monitoring, diagnostic analysis, and support for managing patients with chronic diseases, mainly in the United States.
Generate the Coala-Life Group report
Coala-Life Group is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Coala-Life Group and represent the latest completed financial year (2022). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.